Carboprost tromethamine is a medication primarily used in obstetrics and gynecology for two distinct purposes. First, it is employed as an abortifacient agent in the second trimester of pregnancy, typically between the 13th and 20th weeks of gestation. This is indicated when other methods of abortion have not been successful or in specific conditions such as premature rupture of membranes or the need for a repeat instillation of the drug for fetal expulsion. Second, it is used for the treatment of postpartum uterine hemorrhage due to atony when conventional methods of management have not proven effective. In both scenarios, carboprost tromethamine stimulates myometrial contractions within the uterus, similar to labor contractions, which help evacuate the products of conception in the case of abortion and provide hemostasis in postpartum hemorrhage. However, it can also lead to side effects such as vomiting, diarrhea, transient temperature increases, and, in some cases, bronchoconstriction. It's important to note that the use of carboprost tromethamine for abortion is a medical procedure carried out under specific circumstances and should only be administered by trained healthcare professionals in a clinical setting. Additionally, its use should be closely monitored to ensure both the effectiveness of the treatment and the well-being of the patient.

Carboprost tromethamine Pathway References